IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

- 1-5. (Cancelled)
- 6. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of the formula

$$R_1$$
 $N-S-O$ Polycycle R_2 N $N-S-O$

wherein each of R_1 and R_2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; wherein at least one of R_1 and R_2 is H; and

wherein the group Polycycle is a <u>steroidal</u> ring system comprising at least four rings, at least two of which are fused;

wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2);

wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37° C it would provide a K_m value of less than $50~\mu M$.

7. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound comprising a steroidal ring structure and a sulphamate group of the formula

$$\begin{array}{ccc}
R_1 & O \\
N-S & O \\
R_2 & O
\end{array}$$

wherein each of R_1 and R_2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; wherein at least one of R_1 and R_2 is H; and

wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity

(E.C.3.1.6.2);

wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37° C it would provide a K_m value of less than $50 \, \mu M$.

- 8. (Previously Presented) The pharmaceutical composition of claim 7 wherein the compound is present in an amount to provide 100-500 mg of compound per unit dose.
- 9. (Previously Presented) The pharmaceutical composition according to claim 6, wherein the group Polycycle is a ring system comprising at least four rings, at least three of which are fused.
- 10. (Previously Presented) The pharmaceutical composition according to claim 7, wherein the steroidal ring structure is a residue of a 3-sterol.
- 11. (Previously Presented) The pharmaceutical composition according to claim 10, wherein the sterol is selected from the group consisting of oestrone, dehydroepiandrosterones, substituted oestrones and substituted dehydroepiandrosterones.
- 12. (Previously Presented) The pharmaceutical composition according to any one of claims 6 to 11 wherein R_1 and R_2 are independently selected from H, or a C_1 - C_{10} alkyl; but wherein at least one of R_1 and R_2 is H.
- 13. (Previously Presented) The pharmaceutical composition according to claim 12 wherein R_1 and R_2 are independently selected from H, or C_1 - C_5 alkyl; but wherein at least one of R_1 and R_2 is H.
- 14. (Previously Presented) The pharmaceutical composition according to claim 13 wherein R_1 and R_2 are independently selected from H or methyl; but wherein at least one of R_1 and R_2 is H.

- 15. (Previously Presented) The pharmaceutical composition according to claim 12 wherein R_1 is H and R_2 is H.
- 16. (Previously Presented) The pharmaceutical composition according to any one of claims 7 or 8 wherein the compound is oestrone 3-sulphamate, oestrone-3-N,N-dimethylsulphamate, or oestrone-3-N-monoethylsulphamate.
- 17. (Previously Presented) The pharmaceutical composition according to claim 6 wherein the group Polycycle represents the residue of a sterol.
- 18. (Previously Presented) A pharmaceutical composition according to claim 7 wherein the compound is a compound of the formula

$$R_1$$
 0 Polycycle R_2 0

wherein the group Polycycle represents the residue of a sterol, and wherein R_1 and R_2 are as defined in claim 7.

- 19. (Previously Presented) A pharmaceutical composition according to claim 17 or 18, wherein the sterol is a 3-sterol.
- 20. (Previously Presented) A pharmaceutical composition according to claim 7 wherein the compound is a compound of the formula

wherein the group Polycycle represents the residue of a 3-sterol, and wherein R_1 and R_2 are H.